JP2022540385A5 - - Google Patents
Info
- Publication number
- JP2022540385A5 JP2022540385A5 JP2021578269A JP2021578269A JP2022540385A5 JP 2022540385 A5 JP2022540385 A5 JP 2022540385A5 JP 2021578269 A JP2021578269 A JP 2021578269A JP 2021578269 A JP2021578269 A JP 2021578269A JP 2022540385 A5 JP2022540385 A5 JP 2022540385A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence shown
- antibody
- amino acid
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025003479A JP2025069166A (ja) | 2019-07-02 | 2025-01-09 | 新生児ｆｃ受容体に対する低下した親和性を有する、ｐｓｍａに結合するための抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019902344A AU2019902344A0 (en) | 2019-07-02 | Antibodies | |
| AU2019902344 | 2019-07-02 | ||
| PCT/AU2020/050690 WO2021000018A1 (en) | 2019-07-02 | 2020-07-02 | Antibodies for binding psma with reduced affinity for the neonatal fc receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025003479A Division JP2025069166A (ja) | 2019-07-02 | 2025-01-09 | 新生児ｆｃ受容体に対する低下した親和性を有する、ｐｓｍａに結合するための抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022540385A JP2022540385A (ja) | 2022-09-15 |
| JP2022540385A5 true JP2022540385A5 (enExample) | 2023-07-10 |
| JP7678769B2 JP7678769B2 (ja) | 2025-05-16 |
Family
ID=74100117
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578269A Active JP7678769B2 (ja) | 2019-07-02 | 2020-07-02 | 新生児ｆｃ受容体に対する低下した親和性を有する、ｐｓｍａに結合するための抗体 |
| JP2025003479A Pending JP2025069166A (ja) | 2019-07-02 | 2025-01-09 | 新生児ｆｃ受容体に対する低下した親和性を有する、ｐｓｍａに結合するための抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025003479A Pending JP2025069166A (ja) | 2019-07-02 | 2025-01-09 | 新生児ｆｃ受容体に対する低下した親和性を有する、ｐｓｍａに結合するための抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220323619A1 (enExample) |
| EP (1) | EP3994177A4 (enExample) |
| JP (2) | JP7678769B2 (enExample) |
| KR (1) | KR20220057517A (enExample) |
| CN (1) | CN114555641A (enExample) |
| AU (1) | AU2020299025A1 (enExample) |
| BR (1) | BR112021026663A2 (enExample) |
| CA (1) | CA3141471A1 (enExample) |
| CL (1) | CL2021003563A1 (enExample) |
| IL (1) | IL289523A (enExample) |
| MA (1) | MA56469A (enExample) |
| MX (1) | MX2021015669A (enExample) |
| WO (1) | WO2021000018A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11878312B2 (en) * | 2011-11-21 | 2024-01-23 | Pneumatic Scale Corporation | Centrifuge system for separating cells in suspension |
| US12350686B2 (en) * | 2011-11-21 | 2025-07-08 | Pneumatic Scale Corporation | Centrifuge system for separating cells in suspension |
| US11957998B2 (en) * | 2019-06-06 | 2024-04-16 | Pneumatic Scale Corporation | Centrifuge system for separating cells in suspension |
| EP4294845A4 (en) * | 2021-02-22 | 2026-01-07 | Abdera Therapeutics Inc | Immunoconjugates for targeted radioisotope therapy |
| US20240359144A1 (en) * | 2021-09-01 | 2024-10-31 | Telix Pharmaceuticals (Innovations) Pty Ltd | Aggregate separation method |
| EP4279092A1 (en) | 2022-05-17 | 2023-11-22 | Bayer AG | Radiopharmaceutical complexes targeting prostate-specific membrane antigen |
| RS67935B1 (sr) | 2022-05-17 | 2026-04-30 | Bayer Ag | Radiofarmaceutski kompleksi koji ciljaju na prostata-specifični membranski antigen i njihove kombinacije |
| CN121293357A (zh) | 2022-08-22 | 2026-01-09 | 雅博得乐医疗公司 | Dll3结合分子及其用途 |
| JP2026510493A (ja) * | 2023-03-09 | 2026-04-07 | テリックス ファーマシューティカルズ （イノベーションズ） ピーティーワイ リミテッド | 多機能抗体 |
| WO2024207070A1 (en) * | 2023-04-04 | 2024-10-10 | Telix Pharmaceuticals (Innovations) Pty Ltd | Methods of treating cancers expressing pdgfralpha |
| WO2024207069A1 (en) * | 2023-04-04 | 2024-10-10 | Telix Pharmaceuticals (Innovations) Pty Ltd | Reagents and methods for imaging cancers expressing pdgfralpha |
| KR20250175319A (ko) * | 2023-04-04 | 2025-12-16 | 테릭스 파마슈티컬스 (이노베이션스) 피티와이 엘티디 | Pdgfr알파를 발현하는 암을 치료하는 방법 |
| KR20240164748A (ko) * | 2023-05-12 | 2024-11-20 | 앱클론(주) | 항체 또는 그의 항원 결합 단편, 및 어피바디를 포함하는 이중 항원 표적 단백질 복합체 |
| WO2025184427A1 (en) * | 2024-02-27 | 2025-09-04 | Osteologic Therapeutics, Inc. | Bone-targeted antibodies and methods of use thereof |
| TW202611088A (zh) | 2024-07-23 | 2026-03-16 | 美商雅博得樂醫療公司 | 5t4結合多肽及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1979379B1 (en) * | 2005-12-02 | 2013-09-18 | Dana-Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| CA2766409C (en) * | 2009-07-03 | 2023-04-25 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
| CA3040276A1 (en) * | 2009-12-02 | 2011-06-09 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| TW201817745A (zh) * | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| KR20210090298A (ko) * | 2012-10-30 | 2021-07-19 | 에스퍼란스 파마슈티컬스, 인코포레이티드 | 항체/약물 컨쥬게이트 및 이의 사용 방법 |
| TW201920285A (zh) * | 2013-04-29 | 2019-06-01 | 瑞士商赫孚孟拉羅股份公司 | 遏止FcRn結合之抗IGF-1R抗體及其治療血管性眼疾之用途 |
| CA2904806C (en) * | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
| WO2015054659A1 (en) * | 2013-10-11 | 2015-04-16 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| CN108136012B (zh) * | 2015-08-07 | 2022-10-04 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| CN117534764A (zh) * | 2016-06-06 | 2024-02-09 | 阿布泽纳(英国)有限公司 | 抗体、其用途及其缀合物 |
| GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
-
2020
- 2020-07-02 EP EP20835081.9A patent/EP3994177A4/en active Pending
- 2020-07-02 MX MX2021015669A patent/MX2021015669A/es unknown
- 2020-07-02 WO PCT/AU2020/050690 patent/WO2021000018A1/en not_active Ceased
- 2020-07-02 KR KR1020227002845A patent/KR20220057517A/ko active Pending
- 2020-07-02 JP JP2021578269A patent/JP7678769B2/ja active Active
- 2020-07-02 BR BR112021026663A patent/BR112021026663A2/pt unknown
- 2020-07-02 CA CA3141471A patent/CA3141471A1/en active Pending
- 2020-07-02 AU AU2020299025A patent/AU2020299025A1/en active Pending
- 2020-07-02 MA MA056469A patent/MA56469A/fr unknown
- 2020-07-02 US US17/622,333 patent/US20220323619A1/en active Pending
- 2020-07-02 CN CN202080054212.1A patent/CN114555641A/zh active Pending
-
2021
- 2021-12-29 CL CL2021003563A patent/CL2021003563A1/es unknown
- 2021-12-30 IL IL289523A patent/IL289523A/en unknown
-
2025
- 2025-01-09 JP JP2025003479A patent/JP2025069166A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022540384A5 (enExample) | ||
| JP2025069166A5 (enExample) | ||
| JP2025077045A5 (enExample) | ||
| JP7828375B2 (ja) | 標的分子に対する抗原結合コンストラクト | |
| AU2018388467B2 (en) | Radiolabeling of polypeptides | |
| US11981741B2 (en) | Humanized anti-CD45 antibodies | |
| Reilly | Monoclonal antibody and peptide-targeted radiotherapy of cancer | |
| JP2009268470A (ja) | 抗体分子を用いての腫瘍脈管系の選択的標的化 | |
| CA3205707A1 (en) | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses | |
| Wong et al. | In vitro and in vivo pre-clinical analysis of a F (ab') 2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers | |
| CN100482285C (zh) | 放射性标记的抗纤连蛋白ed-b的抗体l19靶向肿瘤血管的制药用途 | |
| JP2023532081A (ja) | 抗ｄｏｔａ／抗腫瘍抗原二重特異性抗体による事前標的化放射免疫治療のためのｄｏｔａ－ハプテン組成物 | |
| JP2024532372A5 (enExample) | ||
| CA3180690A1 (en) | Cd38 antibodies for treatment of human diseases | |
| WO2024055040A2 (en) | Humanized anti-cd45 antibodies | |
| JP2023518818A5 (enExample) | ||
| CA3208566A1 (en) | Antibodies to igf2r and methods | |
| ES2541907T3 (es) | Secuencias de nucleótidos y proteínas de un anticuerpo dirigido frente a un epítopo común para ferritínas humanas ácidas y básicas, anticuerpos monoclonales o moléculas semejantes a anticuerpo que comprenden estas secuencias y uso de éstos. | |
| TH2401004071A (th) | สารประกอบที่มุ่งเป้า EGFR-cMET และการใช้สิ่งดังกล่าว | |
| Vuillez | Radioimmunotargeting: diagnosis and therapeutic use | |
| Arev et al. | Radioimmunoconjugates of various monoclonal antibodies as potential anticancer therapy-review | |
| AU2024335556A1 (en) | Anti-nectin-4 antibodies and methods of use thereof | |
| TW202607033A (zh) | 抗ｒｏｒ２抗體－放射性核種結合物 | |
| HK40066936A (en) | Antibodies against caix with reduced affinity for the neonatal fc receptor | |
| Nikula | Development of radiolabeled monoclonal antibody constructs: capable of transporting high radiation dose into cancer cells |